SEARCH

SEARCH BY CITATION

References

  • Antiplatelet Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit. Med. J. 2002, 324, 7186.
  • Bombardier , C. , L. Laine , A. Reicin , D. Shapiro , R. Burgos-Vargas , B. Davis , R. Day , M. Ferraz , C. Hawkey , M. Hochberg , T. Kvien , T. Schnitzer & VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New Engl. J. Med. 2000, 343, 15201528.
  • Bresalier , R. , R. Sandler , H. Quan , J. Bolognese , B. Oxenius , K. Horgan , C. Lines , R. Riddell , D. Morton , A. Lanas , M. Konstam & J. Baron : Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial investigators. New Engl. J. Med. 2005, 352, 10921102.
  • Catella-Lawson , F. , M. Reilly , S. Kapoor , A. Cucchiara , S. DeMarco & B. Tournier : Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New Engl. J. Med. 2001, 345, 18091817.
  • Cooper , H. & L. V. Hedges : The handbook of research synthesis. Russel Sage Foundation, New York, 1994.
  • Curtis , S. P. , S. Mukhopadhyay , D. Ramey & A. Reicin : Etoricoxib cardiovascular safety summary. Circulation 2003, 108, S1758.
  • DerSimonian , R. & N. Laird : Meta-analysis in clinical trials. Controlled Clin. Trials 1986, 7, 177188.
  • Eidelman , R. , P. Hebert , S. Weisman & C. H. Hennekens : An update on aspirin in the primary prevention of cardiovascular disease. Arch. Int. Med. 2003, 163, 20062010.
  • Farkouh , M. E. , H. Kirhner , R. A. Harrington , S. Ruland , F. W. Verheugt , T. J. Schnitzer , G. R. Burmester , E. Mysler , M. C. Hochberg , M. Doherty , E. Ehrsam , X. Gitton , G. Krammer , B. Mellein , A. Gimona , P. Matchaba , C. Hawkey & J. J. Chesebro : Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364, 675684.
  • FitzGerald , G. : Coxibs and cardiovascular disease. New Engl. J. Med. 2004, 351, 17091711.
  • Fitzgerald , G. & C. Patrono : The coxibs, selective inhibitors of cyclooxygenase-2. New Engl. J. Med. 2001, 345, 433442.
  • García Rodríguez , L. A. , C. Varas-Lorenzo , A. Maguire , J. Castellsague , A. González-Pérez A , S. Pérez-Guthann & F. Arellano : Non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004, 109, 30003006.
  • García Rodríguez , L. A. , C. Varas-Lorenzo & C. Patrono : Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000, 11, 383387.
  • Graham , D. , D. Campen , R. Hui , M. Spence , C. Cheetham , G. Levy , S. Shoor & W. Ray : Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365, 49965002.
  • Greenland , S. : Basic methods for sensitivity analysis of biases. Int. J. Epidemiol. 1996, 25, 11071116.
  • Gurwitz , J. , J. Avorn & R. Bohn : Initiation of antihypertensive treatment during non-steroidal antiinflammatory drug therapy. J. Amer. Med. Ass. 1994, 272, 781786.
  • Hippisley-Cox , J. & C. Coupland : Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Brit. Med. J. 2005, 330, 13661372.
  • Johnsen , S. P. , H. Larsson , R. E. Tarone , J. K. McLaughlin , B. Norgard , F. Soren & H. T. Sorensen : Risk of hospitalization for myocardial infarction among users of Rofecoxib, Celecoxib, and Other NSAIDs. Arch. Int. Med. 2005, 165, 978984.
  • Johnson , A. : NSAIDs and increased blood pressure. What is the clinical significance. Drug Safety 1997, 17, 277289.
  • Kimmel , S. E. , J. A. Berlin , M. Reilly , J. Jaskowiak , L. Kishel , J. Chittams & B. L. Strom : Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Int. Med. 2005, 142, 157164.
  • Kimmel , S. E. , J. A. Berlin , M. Reilly , J. Jaskowiak , L. Kishel & B. L. Strom : The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Amer. Coll. Cardiol. 2004, 43, 985990.
  • Kurth , T. , R. Glynn , A. Walker , K. Chan , J. Buring , C. Hennekens & J. Gaziano : Inhibition of clinical benefits on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 2003, 108, 11911195.
  • Lévesque , L. E. , J. M. Brophy & B. Zhang : The risk for myocardial infarction with cyclooxygenase-2 inhibitors: A population study of elderly adults. Ann. Int. Med. 2005, 142, 481489.
  • MacDonald , T. & L. Wei : Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 361, 573574.
  • Mamdani , M. , P. Rochon , D. Juurlink , G. Anderson , A. Kopp , G. Naglie , P. Austin & A. Laupacis : Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly. Arch. Int. Med. 2003, 163, 481486.
  • Merck Announces Voluntary Worldwide Withdrawal of VIOXX: http: www.vioxx.comrofecoxibvioxxconsumerindex.jsp . 2004, Sep 30 .
  • Nussmeier , N. , A. Whelton , M. Brown , R. Langford , A. Hoef , J. Parlow , S. Boyce & V. KM : Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New Engl. J. Med. 2005, 352, 10811091.
  • Ott , E. , N. Nussmeier , P. Duke , R. Feneck , R. Alston , M. Snabes , R. Hubbard , P. Hsu , L. Saidman , D. Mangano & Multicenter Study of Perioperative Ischemia (McSPI) Research Group; Ischemia Research and Education Foundation (IREF) Investigators: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 2003, 125, 14811492.
  • Patel , T. N. & K. C. Goldberg : Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch. Int. Med. 2004, 164, 852856.
  • Patrono , C. , B. Coller , J. Dalen , V. Fuster , M. Gent , L. Harker , J. Hirsh & G. Roth : Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2004, 126, 234S264S.
  • Pfizer Statement on New Information Regarding Cardiovascular Safety of Celebrex: http: www.pfizer.comareinvestorsreleases2004prmn20041217.cfm .
  • Rahme , E. , L. Pilote & J. LeLorier : Association between naproxen use and protection against acute myocardial infarction. Arch. Int. Med. 2002, 162, 11111115.
  • Ray , W. , C. Stein , J. Daugherty , K. Hall , P. Arbogast & M. Griffin : COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002a, 360, 10711073.
  • Ray , W. , C. Stein , K. Hall , J. Daugherty & M. Griffin : Non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease: an observational study. Lancet 2002b, 359, 118123.
  • Ross , R. : Atherosclerosis: an inflammatory disease. New Engl. J. Med. 1999, 340, 115126.
  • Schlienger , R. , H. Jick & C. Meier : Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Brit. J. Clin. Pharmacol. 2002, 54, 327332.
  • Silverstein , F. , G. Faich , J. Goldstein , L. Simon , T. Pincus , A. Whelton , R. Makuch , G. Eisen , N. Agrawal , W. Stenson , A. Burr , W. Zhao , J. Kent , J. Lefkowith , K. Verburg & G. Geis : Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J. Amer. Med. Ass. 2000, 284, 12471255.
  • Solomon , D. , R. Glynn & R. Levin : Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med. 2002, 162, 10991104.
  • Solomon , D. , S. Schneeweiss , R. Glynn , Y. Kiyota & R. Levin : Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109, 20682073.
  • Solomon , S. , J. McMurray , M. Pfeffer , J. Wittes , R. Fowler , P. Finn , W. Anderson , A. Zauber , E. Hawk , M. Bertagnolli & for the Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl. J. Med. 2005, 352, 10711080.
  • Watson , D. , T. Rhodes & R. Holmes : Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. 2002, 162, 11051110.
  • White , W. , G. Faich , A. Whelton , C. Maurath , N. Ridge , K. Verburg , G. Geis & J. Lefkowith : Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Amer. J. Cardiol. 2002, 89, 425430.